IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma

@inproceedings{Xu2015IL8PA,
  title={IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma},
  author={C-F Xu and Theron S Johnson and Jes{\'u}s Garc{\'i}a-Donas and Toni K Choueiri and Cora N Sternberg and Ian D Davis and Nan X Bing and Keith C Deen and Zhongyu Xue and Linda D. McCann and Efra{\'i}n Esteban and John C. Whittaker and Colin F Spraggs and Cristina Rodr{\'i}guez-Antona and Lini N. Pandite and Robert J Motzer},
  booktitle={British Journal of Cancer},
  year={2015}
}
Background:We evaluated germline single nucleotide polymorphisms (SNPs) for association with overall survival (OS) in pazopanib- or sunitinib-treated patients with advanced renal cell carcinoma (aRCC).Methods:The discovery analysis tested 27 SNPs within 13 genes from a phase III pazopanib trial (N=241, study 1). Suggestive associations were then pursued in two independent datasets: a phase III trial (COMPARZ) comparing pazopanib vs sunitinib (N=729, study 2) and an observational study of… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 10 times over the past 90 days. VIEW TWEETS
11 Citations
41 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Adjuvant therapy

  • T 1063–1071. Janowitz, SJ Welsh, K Zaki, P Mulders, T Eisen
  • 2013
Highly Influential
1 Excerpt

Similar Papers

Loading similar papers…